On January 6, 2022 Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company developing next-generation mental health and oncology treatments by leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body, reported that Dr. Joseph Tucker, Chief Executive Officer of Enveric Biosciences, will participate in the H.C. Wainwright BioConnect Conference to be hosted virtually on January 10-13, 2022 (Press release, Jay Pharma, JAN 6, 2022, https://www.enveric.com/news/enveric-biosciences-to-participate-in-the-h-c-wainwright-bioconnect-conference-on-january-10-13-2022/ [SID1234598337]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Tucker’s corporate presentation will be available on-demand starting Monday, January 10th. Register to attend here.

For more information about the conference, or to schedule a one-on-one meeting with Enveric’s management team, please contact your appropriate representative directly, or send an email to H.C. Wainwright at [email protected], or KCSA Strategic Communications at [email protected].